B
Benedikt Gahn
Researcher at Baylor College of Medicine
Publications - 7
Citations - 599
Benedikt Gahn is an academic researcher from Baylor College of Medicine. The author has contributed to research in topics: CTL* & Cytotoxic T cell. The author has an hindex of 7, co-authored 7 publications receiving 586 citations. Previous affiliations of Benedikt Gahn include University of Kiel & Houston Methodist Hospital.
Papers
More filters
Journal ArticleDOI
Cytotoxic T lymphocyte therapy for epstein-barr virus+ Hodgkin's disease
Catherine M. Bollard,Catherine M. Bollard,Laura K. Aguilar,Karin Straathof,Benedikt Gahn,M. Helen Huls,Alexandra Rousseau,John W. Sixbey,M. Victoria Gresik,George Carrum,George Carrum,Melissa M. Hudson,Dagmar Dilloo,Adrian P. Gee,Adrian P. Gee,Malcolm K. Brenner,Malcolm K. Brenner,Cliona M. Rooney,Cliona M. Rooney,Helen E. Heslop,Helen E. Heslop +20 more
TL;DR: The performance and fate of these human tumor antigen–specific T cells in vivo suggests that they might be of value for the treatment of EBV+ Hodgkin lymphoma.
Journal ArticleDOI
Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen : A potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma
Benedikt Gahn,Fernando Siller-López,Angela D. Pirooz,Eric Yvon,Stephen Gottschalk,Richard Longnecker,Malcolm K. Brenner,Helen E. Heslop,Estuardo Aguilar-Cordova,Cliona M. Rooney +9 more
TL;DR: In vitro stimulation of CTLs with DCs genetically modified with 2 E1/E3‐deleted recombinant adenoviruses effectively transduce DCs and direct the generation of LMP2A‐specific C TLs will be a potent strategy in Hodgkin's lymphoma immunotherapy.
Journal ArticleDOI
Identification of a naturally processed HLA-DR-restricted T-helper epitope in Epstein-Barr virus nuclear antigen type 1.
TL;DR: In this study, the TEPITOPE software program was used to predict promiscuous class II epitope candidates and the inclusion of the naturally processed EBNA1482 epitope in vaccine constructs could enhance immune responses against EBV-positive cancers.
Journal Article
Immunotherapy for Hodgkin's disease.
Cliona M. Rooney,Catherine M. Bollard,M. H. Huls,Benedikt Gahn,St Gottschalk,Hans Joachim Wagner,Robert H. Anderson,H. G. Prentice,Malcolm K. Brenner,Helen E. Heslop +9 more
TL;DR: Clinical studies produced resolution of B symptoms and mixed tumor responses including one complete remission of residual disease remaining after autologous bone marrow transplant and future clinical studies will test the efficacy of CTL with improved antigen-specificity and resistance to Hodgkin immune evasion strategies.
Journal ArticleDOI
Immunotherapy to reconstitute immunity to DNA viruses
TL;DR: Current efforts focus on optimizing adoptive immunotherapy approaches and developing strategies for generating T cells specific for multiple viruses to provide broader protection.